ArticleFrontiers in oncology2025
Construction of predictive models for contralateral occult thyroid carcinoma and central lymph node metastasis in unilateral papillary thyroid carcinoma using machine learning.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to develop predictive models based on preoperative clinicopathological and imaging features to accurately assess the individual risk of contralateral occult thyroid carcinoma (OTC) and determine the number of central lymph node metastasis (CLNM) in patients with unilateral papillary thyroid carcinoma, thereby providing actionable guidance for surgical planning. Methods: Seven widely-used machine learning algorithms were employed to develop predictive models. Hyperparameter tuning was performed via cross-validation in combination with grid search. The models were subsequently trained and evaluated by using the optimal hyperparameter combinations. To facilitate comparative analysis, ROC curves, calibration curves were generated and DCA was performed. The optimal model was then selected on the basis of this comprehensive evaluation. Furthermore, a clinical prediction model was constructed utilizing the significant predictors identified. Results: The logistic regression model was identified to be the optimal predictive model. For the clinical prediction model of OTC, the following independent variables were incorporated: body mass index, and ultrasonographic findings, including capsular disruption, number of malignant nodules within a unilateral lobe, sum of the longest diameter (SLD) of tumors, and the presence of isthmic malignant nodule(s). This model yielded an area under the ROC curve (AUC) of 0.74 and 0.70 in the training and validation cohorts, respectively. For the clinical prediction model of ≥5 CLNM, the incorporated independent variables included: age, sex, chronic lymphocytic thyroiditis, and ultrasonographic features covering malignant nodules located near the isthmus, SLD, capsular disruption, and calcification. This model produced an AUC of 0.75 and 0.71 in the training and validation cohorts, respectively. Decision curve analysis indicated that clinical interventions guided by the two models could provide net benefit within threshold probability ranges of 10% to 90% and 10% to 70% for patients with PTC. And the calibration curves demonstrated a good agreement between model predictions and actual observations. Conclusion: This study developed and validated clinical prediction models to estimate the risk of contralateral OTC and the presence of ≥5 CLNM in patients with unilateral PTC. These models were designed to prevent overtreatment in low-risk patients while providing evidence-based guidance for decision-making about treatment choice in high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.